Polymyalgia rheumatica (PMR) special interest group at OMERACT 11: Outcomes of importance for patients with PMR

Journal of Rheumatology

Volumn 41, Issue 4, 2014, Pages 819-823

  Mackie, Sarah L ^a   Arat, Seher ^b   Da Silva, Jose ^c   Duarte, Catia ^c   Halliday, Sue ^d   Hughes, Rod ^e   Morris, Marianne ^f   Pease, Colin T ^g   Sherman, Jeffrey W ^h   Simon, Lee S ⁱ   Walsh, Maggie ^e   Westhovens, René ^j   Zakout, Samy ^k   Kirwan, John R ^k  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^d Polymyalgia Rheumatica Giant Cell Arteritis (PMRGCA)   (United Kingdom)

^e ASHFORD AND ST PETER'S HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^g LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^h Horizon Therapeutics   (United States)

ⁱ SDG LLC   (United States)

^j UNIVERSITY OF LEUVEN   (Belgium)

^k UNIVERSITY OF BRISTOL   (United Kingdom)

more..

Author keywords

Core set; Omeract; Outcome and process assessment; Pain; Polymyalgia rheumatica; Stiffness

Indexed keywords

GLUCOCORTICOID; STEROID;

ANXIETY; ARTHRALGIA; CLINICAL RESEARCH; COMORBIDITY; CONSULTATION; DELAYED DIAGNOSIS; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FATIGUE; HUMAN; JOINT FUNCTION; JOINT STIFFNESS; MORNING STIFFNESS; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REVIEW; RHEUMATIC POLYMYALGIA; SLEEP DISORDER; SYSTEMATIC REVIEW (TOPIC); VISUAL ANALOG SCALE; CONSENSUS DEVELOPMENT; FEMALE; INFORMATION PROCESSING; LONGITUDINAL STUDY; MALE; PAIN MEASUREMENT; PATIENT SATISFACTION; POLYMYALGIA RHEUMATICA; PRACTICE GUIDELINE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; FEMALE; FOCUS GROUPS; HUMANS; LONGITUDINAL STUDIES; MALE; PAIN MEASUREMENT; PATIENT SATISFACTION; POLYMYALGIA RHEUMATICA; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STEROIDS;

EID: 84897425070     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131254     Document Type: Review

References (17)

1. Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011;63:633-9.
2. Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K, Silverman B, et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 2007;57:803-9.
3. Matteson EL. Clinical guidelines: unravelling the tautology of polymyalgia rheumatica. Nat Rev Rheumatol 2010;6:249-50.
4. Mackie SL, Hensor EM, Haugeberg G, Bhakta B, Pease CT. Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology 2010;49:716-22.
5. Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology 2010;49:186-90.
6. World Health Organization. International classification of functioning, disability and health: ICF, WHO, Geneva, Switzerland, 2001. [Internet. Accessed December 11, 2013.] Available from: http://www.who.int/classifications/icf/en/
7. Dasgupta B, Salvarani C, Schirmer M, Crowson CS, Maradit-Kremers H, Hutchings A, et al. Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J Rheumatol 2008;35:270-7.
8. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206-9.
9. Hewlett S, Cockshott Z, Byron M, Kitchen K, Tipler S, Pope D, et al. Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005;53:697-702.
10. Minnock P, Kirwan J, Veale D, Fitzgerald O, Bresnihan B. Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis. Clin Exp Rheumatol 2010;28:401-4.
11. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
12. Hewlett S, Wit Md, Richards P, Quest E, Hughes R, Heiberg T, et al. Patients and professionals as research partners: challenges, practicalities, and benefits. Arthritis Rheum 2006;55:676-80.
13. Chalmers I. Confronting therapeutic ignorance: Tackling uncertainties about the effects of treatments will help to protect patients. BMJ 2008;337:a841.
14. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
15. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77-101.
16. Zakout S, Kirwan Jr. Polymyalgia rheumatica has a nocturnal rise in serum interleukin-6 which is almost completely suppressed by nighttime prednisone [abstract]. Arthritis Rheum 2011;63 Suppl:S27.
17. US Department of Health and Human Services Food and Drug Administration (FDA). Guidance for industry - patient-reported outcome measures: use in medical product development to support labeling claims. [Internet. Accessed December 11, 2013.] Available from http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM19328 2.pdf